NCT04458610View on ClinicalTrials.gov

Zanubrutinib and Rituximab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

May 26, 2020

Primary Completion Date

May 26, 2026

Study Completion Date

May 26, 2026

Conditions
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Interventions
BIOLOGICAL

Rituximab

Given IV

DRUG

Zanubrutinib

Given PO

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER